Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4231-4235

  Zhou, Xiao Jian ^a   Swan, Suzanne ^b,c   Smith, William B ^d   Marbury, Thomas C ^e   Dubuc Patrick, Gloria ^a   Chao, George C ^a   Brown, Nathaniel A ^a  

^a Idenix Pharmaceuticals Inc   (United States)

^b DAVITA CLINICAL RESEARCH   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d New Orleans Center for Clinical Research   (United States)

^e ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; TELBIVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LOOSE FECES; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINUS CONGESTION; URINALYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES;

EID: 36749022154     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00557-07     Document Type: Article

References (12)

1. Cretton-Scott, E., X. J. Zhou, E. G. Bridges, B. Tennant, A. Juodawlkis, G. Grosselin, J. L. Imbach, C. Pierra, D. Dukhan, R. F. Schinazi, J. P. Sommadossi, and E. M. Bryant. 1999. Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine in woodchucks and monkeys. Antivir. Ther. 4:A124.
2. Fournier, A., and J. M. Achard. 2000. Mnemotechnical note on the use of Cockcroft creatinine clearance formula for the validation of a 24-h urine collection. Nephrol. Dial. Transplant. 15:1677-1678.
3. Heald, A. E., P. H. Hsyu, G. J. Yuen, P. Robinson, P. Mydlow, and J. A. Bartlett. 1996. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40:1514-1519.
4. Hernandez-Santiago, B., L. Placidi, E. Cretton-Scott, A. Faraj, E. G. Bridges, M. L. Bryant, J. Rodriguez-Orengo, J. L. Imbach, G. Gosselin, C. Pierra, D. Dukhan, and J. P. Sommadossi. 2002. Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. 46:1728-1733.
5. Hu, P., J. Jiang, H. Wang, K. Pietropaolo, G. C. Chao, N. A. Brown, and X. J. Zhou. 2006. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J. Clin. Pharmacol. 46:999-1007.
6. Lai, C. L., N. Leung, E. K. Teo, M. Tong, F. Wong, H. W. Hann, S. Han, T. Poynard, M. Myers, G. Chao, D. Lloyd, N. Brown, and the Telbivudine Phase II Investigator Group. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
7. Lai, C. L., S. G. Lim, N. A. Brown, X. J. Zhou, D. M. Lloyd, Y. M. Lee, M. F. Yuen, G. C. Chao, and M. W. Myers. 2004. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719-726.
8. Standring, D. N., E. G. Bridges, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, E. Cretton-Scott, R. F. Schinazi, M. Myers, M. L. Bryant, and J. P. Sommadossi. 2001. Antiviral β-L-nucleosides specific for the hepatitis B virus infection. Antivir. Chem. Chemother. 12:119-129.
9. Zhou, X. J., B. A. Fielman, D. M. Lloyd, G. C. Chao, and N. A. Brown. 2006. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob. Agents Chemother. 50:2309-2315.
10. Zhou, X. J., S. G. Lim, D. M. Lloyd, G. C. Chao, N. A. Brown, and C. L. Lai. 2006. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob. Agents Chemother. 50:874-879.
11. Zhou, X. J., D. M. Lloyd, C. C. Chao, and N. A. Brown. 2006. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol. 46:275-281.
12. Zhou, X. J., T. C. Marbury, H. W. Alcorn, W. B. Smith, P. G. Dubuc, G. C. Chao, and N. A. Brown. 2006. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob. Agents Chemother. 50:1721-1726.